Skip to content
Screener

Immunome IMNM Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
$2M-33.3%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$4.22M+42.2%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$1.53M+2,835%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$1.43M+260%

Other financials

Income statement

See full
Revenue--100%
Operating income-$78.1M-68.1%
Net income-$73.1M-68.5%
EPS (diluted)-$0.65-30.0%

Balance sheet

See full
Cash & equivalents$217.7M+51.3%
Total debt$4.7M+14.4%
Total equity$525.1M+95.0%
Total assets$565.4M+90.8%

Cash flow

See full
Operating cash flow-$61.7M-24.9%
CapEx$2.2M+140%
Free cash flow-$63.9M-27.0%

Valuation

See full
Market cap$2.83B+237%
Enterprise value$2.62B+274%

Profitability

See full
Operating margin-5,947.9%-12,002pp
Net margin-5,593.8%-11,284pp
FCF margin-5,118.9%-8,601pp

Returns & leverage

See full
Return on equity-64%-11.2pp
Debt / equity0.0×
Current ratio15.1×+3.0×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The source filing: Immunome’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:10 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344636
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization1,5601,248
Amortization of right-of-use asset354198
Accretion of discounts on marketable securities(446)(2,023)
Share-based compensation expense16,75211,050
Loss on disposal of property and equipment78891
Changes in operating assets and liabilities:
Prepaid expenses and other assets(11,995)(5,303)

Item 1. Financial Statements.

FAQ

What is Immunome's accretion (amortization) of discounts and premiums, investments?
Immunome (IMNM) reported accretion (amortization) of discounts and premiums, investments of $446K in Q2 2026.
How has Immunome's accretion (amortization) of discounts and premiums, investments changed year-over-year?
Immunome's accretion (amortization) of discounts and premiums, investments decreased by 63.0% year-over-year, from $1.21M to $446K.
What does accretion (amortization) of discounts and premiums, investments mean?
This represents the non-cash adjustment to interest income or expense resulting from the amortization of premiums or discounts on debt securities held as investments. It reflects the gradual alignment of the security's carrying value with its par value over the remaining term to maturity. Investors use this to understand the effective yield of the company's investment portfolio beyond nominal coupon payments.

Ask your AI about Immunome's accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude